Spots Global Cancer Trial Database for ITIL-168 in Advanced Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ITIL-168 in Advanced Melanoma
Official Title: A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
Study ID: NCT05050006
Conditions
Interventions
Study Description
Brief Summary: DELTA-1 is a phase 2 clinical trial to evaluate the efficacy and safety of ITIL-168 in adult subjects with advanced melanoma who have previously been treated with a PD-1 inhibitor. ITIL-168 is a cell therapy derived from a patient's own tumor-infiltrating immune cells (lymphocytes; TILs).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California San Diego, Moores Cancer Center, La Jolla, California, United States
The Angeles Clinic and Research Institute, Los Angeles, California, United States
USC - Norris Comprehensive Cancer Center, Los Angeles, California, United States
UCLA Health - Westwood Cancer Care, Los Angeles, California, United States
Stanford Cancer Institute, Stanford, California, United States
University of Colorado - Anschutz Cancer Pavilion, Aurora, Colorado, United States
Georgetown University Medical Center, Washington, District of Columbia, United States
The University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Orlando Health Cancer Institute, Orlando, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Rush University Cancer Center, Chicago, Illinois, United States
Loyola University Chicago, Maywood, Illinois, United States
University of Louisville, James Graham Brown Cancer Center, Louisville, Kentucky, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States
Atlantic Health System - Morristown Medical Center, Morristown, New Jersey, United States
Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
St. Luke's University Health Network, Bethlehem, Pennsylvania, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Cambridge University Hospital NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, England, United Kingdom
Contact Details
Name: Instil Study Director
Affiliation: Instil Bio, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
